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 Bacterial heteroresistance has been increasingly identified as an important 29 
phenomenon for many combinations of antibiotic and bacteria, including vancomycin 30 
in Staphylococcus aureus, carbapenems in Acinetobacter baumannii and 31 
Pseudomonas aeruginosa, and penicillin in Streptococcus pneumonia. We identified 32 
an isolate of Salmonella from food which yielded a population that demonstrated 33 
heteroresistance to ciprofloxacin. Population analyses profile curves identified a 34 
resistant subpopulation at a low frequency (10-9 to 10-7). Whole Genome Sequencing 35 
and pulsed-field gel electrophoresis analyses confirmed that these two 36 
subpopulations are isogenic with 6 single-nucleotide polymorphisms and two small 37 
deletions distinguishing the resistant subpopulation from the susceptible. Both the 38 
resistant subpopulation and the parental population possessed a T57S substitution in 39 
ParC and carried qnrS. The resistant subpopulation was distinguished by over-40 
expression of acrB and acrF and a deletion within rsxC and associated alteration in 41 
expression of soxS. The resistant population had a competitive advantage against 42 
the parental population when grown in the presence of bile salts but was attenuated 43 
in the adhesion and invasion of human intestinal cells. The presence of ciprofloxacin 44 
heteroresistant populations in food animals may represent a threat as traditional 45 
susceptibility testing cannot easily identify this phenomenon.  46 
Importance  47 
 We report the identification of ciprofloxacin heteroresistance in Salmonella 48 
isolated from chicken meat. Heteroresistance is a concern as the presence of 49 
resistant sub populations is often missed by susceptibility testing and ciprofloxacin 50 
remains an important therapy for salmonellosis. We determined that heteroresistance 51 
resulted from a combination of mutations in fluoroquinolone target genes and 52 
overexpression of efflux pumps associated with a deletion in rsxC. This study alerts 53 
that heteroresistance to ciprofloxacin exists in Salmonella in the food chain and that 54 




Non-typhoidal Salmonella are one of the most important foodborne pathogens 57 
and a leading cause of diarrhea worldwide. Non-typhoidal Salmonella infections are 58 
usually self-limiting, but severe infections can occur (1, 2). Fluoroquinolones (FQs), 59 
especially ciprofloxacin, are one of the drugs of choice for the treatment of 60 
salmonellosis although resistance to FQs has emerged (3). In gram-negative 61 
bacteria, FQ resistance is primarily due to mutations in target genes encoding for 62 
DNA gyrase and topoisomerase IV(4). Other mechanisms of FQ resistance include 63 
over-production of chromosomal multidrug resistance (MDR) efflux pumps (5) and 64 
acquisition of plasmid-mediated quinolone resistance (PMQR) determinants. 65 
Amongst the multiple MDR efflux pumps, AcrAB, which belongs to the resistance-66 
nodulation-cell division (RND) family, is the most important determinant of FQ efflux 67 
(6). In Salmonella, AcrAB is regulated by the local repressor AcrR and global 68 
regulators RamA, MarA and SoxS (7). PMQRs include the ‘Qnr’ proteins, a variant of 69 
the common aminoglycoside acetyltransferase, AAC(6’)-Ib-cr (8), and efflux pumps 70 
QepA (9, 10) and OqxAB (11). Both MDR efflux and PMQRs confer relatively modest 71 
changes in susceptibility which do not result in clinical ‘breakpoint’ resistance without 72 
a synergistic mutation within gyrA. 73 
Heteroresistance is a phenomenon whereas a seemingly isogenic population 74 
contains a subpopulation with different susceptibility to a given antibiotic than the 75 
majority. Studies in recent years have reported the presence of heteroresistance in 76 
clinical settings which have been associated with treatment failure (12). Upon 77 
antibiotic exposure, the proportion of resistant mutants can increase leading to 78 
selection of a resistant population and therapy failure (13). Heteroresistance is 79 
thought to be an important intermediate stage before the development of full 80 
resistance (14). A population with a heterogeneous level of drug susceptibility gains 81 
robustness in terms of ability to survive antibiotic exposure without committing all 82 
members of the population to become resistant if there is an associated fitness cost 83 
in drug-free conditions (14-17). The first description of heteroresistance was by 84 
Alexander and Leidy in 1947 (18, 19) who noticed subpopulations with altered 85 
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streptomycin susceptibility in Haemophilus influenzae. Jevons (in 1960) reported two 86 
Staphylococcus aureus subpopulations with quite different methicillin susceptibilities 87 
(20). More recently there are increasing reports of heteroresistance including 88 
cephalosporins and penicillins heteroresistance in Acinetobacter baumannii (21), 89 
penicillin heteroresistance in Streptococcus pneumoniae (14) and commonly 90 
imipenem and meropenem in Pseudomonas aeruginosa (22). Heteroresistance to 91 
colistin, which is often the only effective antibiotic against widely resistant isolates 92 
and used a last resort therapy has been reported from multidrug-resistant 93 
Acinetobacter baumannii (13, 23). 94 
Heteroresistance to ciprofloxacin has been reported but not in Salmonella (17), 95 
given the importance of Salmonella infections and use of FQs in treatment 96 
development of heteroresistance would be a concern. In this study, we isolated a 97 
ciprofloxacin heteroresistant Salmonella from animals and investigated mechanisms 98 




Identification of ciprofloxacin heteroresistance amongst Salmonella isolates  101 
A total of 61 Salmonella isolates were obtained from 36 chicken meat and 47 102 
pork specimens. Among the 61 Salmonella isolates, ciprofloxacin resistance (MICCIP 103 
range: 1-32 mg/L) and susceptibility (MICCIP range: 0.008-0.5 mg/L) rates were 104 
11.48% and 88.52% respectively. PAP of the ciprofloxacin susceptible isolates 105 
identified the presence of one Salmonella Agona strain which was isolated from 106 
chicken meat displaying heteroresistance to CIP (Fig. 1). The PAP curve indicated 107 
that the frequencies of the presence of resistant subpopulations were between 10-9 to 108 
10-7. PFGE profiles of Xbal-digested genomic DNA indicated identical banding 109 
profiles between the parent and heteroresistant population (Fig. 1). Antimicrobial 110 
susceptibility testing of the resistant subpopulation showed a 16-fold increases in 111 
MICCIP compared to its parent strain (Table 1). The heteroresistant strain was of 112 
multilocus sequence type ST13 (Table 1). 113 
Resistance mechanisms contributing to ciprofloxacin heteroresistance in 114 
Salmonella 115 
We analyzed known mechanisms of FQ resistance in this pair of strains to 116 
identify any differences between the susceptible and resistant isolates. The MIC of 117 
ciprofloxacin of HZC9-R (4 mg/L) increased 16-fold relative to native strain HZC9 118 
(0.25 mg/L) which is considered intermediate by CLSI breakpoints, and resistant by 119 
EUCAST rules. A T57S substitution in ParC and the presence of the PMQR gene 120 
qnrS were found in both strains. Expression of both acrB and acrF in HZC9-R were 121 
raised (2.43-fold and 1.57-fold, respectively) compared to HZC9 (Table1) and 122 
expression of qnrS in HZC9-R was significantly higher than in HZC9 (Fig. 2), 123 
suggesting the involvement of efflux pump expression and qnrS expression in 124 
ciprofloxacin resistance in HZC9-R. Supporting the idea that efflux expression was 125 
important in dictating the phenotype of HZC9-R, accumulation assays revealed 126 
significantly less accumulation of resazurin in this strain compared to the parent (Fig 127 
2). 128 




Growth curves showed both subpopulations in LB broth required similar time to 131 
reach stationary phase but HZC9-R achieved a slightly lower cell density than the 132 
susceptible subpopulations (Data not shown). Competitive growth assays of the sub 133 
populations against a common wild-type strain (marked by the presence of the lac 134 
operon allowing blue-white screening) showed that subpopulation HZC9-R was more 135 
competitive than the parent population (Fig. 3). 136 
We also assessed the competitive ability between the resistant and susceptible 137 
subpopulations directly in 0%, 0.1%, and 1% bile by pyrosequencing in antibiotic-free 138 
LB broth in three independent experiments. The mean competition coefficients 139 
between HZC9-R and HZC9 were 2.03, 3.00 and 3.57 (Fig. 3). This result indicated 140 
that resistant Salmonella HZC9-R had a competitive growth advantage in the 141 
presence of bile. 142 
Association and invasion ability of resistant strain and its parent strains  143 
To determine if there were any differences in the association and invasion ability 144 
of this pair of strains, we measured the ability of each to associate and invade INT 145 
407 cells in vitro (Fig. 4). Results are expressed as the percentage of the inoculum 146 
that effectively associated and invaded the INT 407 cells. HZC9-R (MICCIP=4 mg/L) 147 
strain had lower virulence than HZC9 (MICCIP=0.25 mg/L). 148 
The virulence of each subpopulation was also investigated by using Galleria 149 
mellonella larvae infection model. The result was consistent with the association and 150 
invasion assay in that HZC9 was more virulent than HZC9-R (Fig. 4).                 151 
Genomic analysis 152 
Whilst the initial investigations suggested efflux over-expression as a mechanism 153 
determining the phenotype of HZC9-R there was no immediate reason for this. 154 
Hybrid genome assemblies based on nanopore and illumina data were prepared for 155 
both strains. Each had a single chromosome (4.9Mb) and three distinct plasmids of 156 
(92kb, 49kb and 10kb) as shown in table S1. There were a small number of 157 
differences present between the strains including 6 SNPs as well as a small number 158 
of deletions, including a 250bp deletion within rsxC present in HZC9-R (Table S2 and 159 
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Fig. S1).  160 
Paraquat induces immediate soxS expression in HZC9-R  161 
RsxC has been shown in E. coli to constitute a reducing system to reset 162 
expression of soxS once induced by reducing SoxR but has not been identified as 163 
having a role in ciprofloxacin resistance in Salmonella. We measured expression and 164 
sensitivity to induction of soxS in HZC9-R and tested the impact of inactivating rsxC 165 
in HZC9. The results showed that expression of soxS in HZC9-R was higher than in 166 
HCZ9 and responded to induction much more quickly (Fig. 8). Furthermore, 167 
inactivation of rsxC in HZC9 led to decreased susceptibilities (2-4 fold) to various 168 

































Heteroresistance has been recognized as an important step in the development 200 
of highly resistant populations but often cannot be detected by traditional antibiotic 201 
susceptibility testing which can therefore give misleading sensitivity results that can 202 
lead to treatment failures (17). Heteroresistant phenomena, which render 203 
compromising activity of clinical relevant antimicrobials, are increasingly reported in a 204 
variety bacteria, including Haemophilus influenzae, Staphylococcus aureus, 205 
Acinetobacter baumannii, Streptococcus pneumonia, and Pseudomonas aeruginosa 206 
(13, 14, 20-23). In the present study, we for the first time identified one ciprofloxacin 207 
heteroresistant Salmonella strain HZC9 with a subpopulation of resistant cells with an 208 
elevated MICCIP 8-fold higher than its parent strain. This indicates that this resistant 209 
subpopulation is likely to expand and confer full resistance if ciprofloxacin is chosen 210 
for therapy. This raises the likelihood that traditional testing cannot easily identify the 211 
presence of ciprofloxacin heteroresistance and the necessity of careful interpretation 212 
of antibiotic susceptibility. To explore whether these resistant subpopulations have 213 
any fitness cost we compared their ability to grow in media alone and in the presence 214 
of bile, a proxy for conditions in the gut. The resistant strain grew more slowly than 215 
the sensitive counterpart in all conditions in isolation (data not shown) but was able to 216 
outcompete the resistant strain when mixed together suggesting some interplay 217 
between the subpopulations. 218 
To clarify the underlying mechanisms contributing to the heteroresistant 219 
phenotypes, we analyzed possible mechanisms among resistant and susceptible 220 
subpopulations. Both resistant and susceptible strains (HZC9-R and HZC9) harbored 221 
a single amino acid change of T57S in ParC. This substitution has been suggested to 222 
be seen in some serovars without a role in FQ resistance, one study speculated that 223 
Salmonella enterica serovar Typhimurium, serovar Schwarzengrund, and serovar 224 
Hadar each have a different role from parC T57S mutation in quinolone resistance 225 
(24), however data from another study suggested that a T57S mutation in ParC 226 
increased ciprofloxacin susceptibility of isolates (25). Overexpression of acrB (2.43-227 
fold) and acrF (1.57-fold) and significantly higher expression of qnrS were detected in 228 
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HZC9-R relative to HZC9 which could help explain the ciprofloxacin resistance. 229 
Several studies have shown that the acquisition of mutations that increase efflux, 230 
mainly due to the overexpression of AcrAB, are key steps along with mutations in 231 
QRDRs in the development of quinolone resistance in Salmonella (25, 26). Of the 6 232 
SNPs present between the strains, none were in known regulators of acrAB or 233 
acrEF. Comparison of the genomes of the two strains revealed a ~250 bp deletion of 234 
gene rsxC on the chromosome in HZC9-R. Both expression of soxS in HZC9-R and 235 
the 2-4 fold decreased susceptibilities to drugs and dyes in HZC9 ∆rsxC::tetR mutant 236 
suggested that increased efflux in HZC9-R was activated by increased soxS activity 237 
which resulted from mutation of rsxC. Therefore, inactivation of rsxC is a relevant 238 
mechanism of fluoroquinolone resistance in Salmonella which should be considered 239 
when searching for the genetic basis for resistance. 240 
In conclusion, to the best of our knowledge, this is the first study to report Salmonella 241 
ciprofloxacin heteroresistance. Ciprofloxacin heteroresistance in Salmonella strains 242 
can be explained by a combination of target gene mutations, overexpression of efflux 243 
pumps caused by rsxC mutation and carriage of a PMQR. The present study alerts 244 
that ciprofloxacin heteroresistance exists in isolates from the food chain and will not 245 















Materials and methods  259 
Salmonella isolation, Serotyping, and Antimicrobial susceptibility testing 260 
61 Salmonella strains were isolated from 36 chicken meat and 47 pork 261 
specimens obtained in 2016 from four supermarkets, in Guangzhou, Guangdong, 262 
China. Approximately 25 g samples cut into pieces were put into 200 mL buffered 263 
peptone water (BPW) and then incubated at 37°C for 12 h. 1 mL aliquots of BPW 264 
cultures were then transferred to 10 mL of selenite cysteine broth and incubated at 265 
37°C for 24 h. The enriched culture was streaked onto chromogenic medium 266 
selective for Salmonella (CHROM agar Microbiology, France) and incubated for 267 
another 24 h at 37°C. Single purple colonies were selected from each plate and then 268 
confirmed as Salmonella using the API20E system (bioMérieux, Marcy l’Étoile, 269 
France) and identified by MALDI-TOF MS (Axima-Assurance-Shimadzu). Salmonella 270 
isolates were serotyped using Salmonella specific O and H antigens (Statens Serum 271 
Institut, Denmark) by the slide agglutination test according to the Kauffmann-White 272 
scheme. MICs of ciprofloxacin were determined in triplicate for each bacterial strain 273 
using the broth microdilution method according to the CLSI reference methods. 274 
Escherichia coli ATCC 25922 was used as a quality control strain. The genetic 275 
relatedness of heteroresistant strains was initially assessed by PFGE after Xbal-276 
digestion of genomic DNA using a CHEF-MAPPER System (Bio-Rad Laboratories, 277 
HercµLes, CA), as previously described (27). 278 
Population analyses profiling (PAP) 279 
PAP was conducted for resistance to ciprofloxacin as described previously with 280 
some modifications (21). Briefly, bacteria were streaked out on Muller-Hinton agar 281 
plates and incubated at 37°C for 24 h. Single colonies were sub-cultured in 5 mL of 282 
Muller-Hinton broth and grown overnight. Cultures were serially diluted and plated 283 
onto Muller-Hinton agar plates containing 2-fold dilutions of ciprofloxacin at 284 
concentrations ranging from 0.5 to 16-fold MIC. A 10-6 dilution of the culture was 285 
plated onto Muller-Hinton agar plates containing no drug for determination of colony 286 
numbers which were counted after incubation at 37°C for 48 h. Three independent 287 
assays were performed, and mean colony numbers were calculated and plotted on a 288 
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semi-logarithmic graph with colony numbers on the vertical axis and drug 289 
concentration on the horizontal axis. Colonies grown on drug-containing plates (4 to 290 
16-fold MIC) were sub-cultured in drug-free plates for 1 week and MICs were 291 
determined using the broth micro-dilution method. 292 
Detection of mutations within QRDRs, presence of PMQR genes, and 293 
expression of acrB, acrF and qnrS 294 
Mutations in gyrA, gyrB, parC, and parE were detected by PCR (28) and 295 
sequencing, results were compared against with the genome of Salmonella 296 
Typhimurium LT2. The presence of PMQR determinants qnrA, qnrB, qnrC, qnrD, 297 
qnrS, aac(6’)-Ib-cr, qepA, and oqxAB) was analyzed by PCR using primers and 298 
conditions described previously (29).  299 
For gene expression analyses, bacterial strains were grown in minimal media to 300 
an OD600 of 0.6, and total RNA was isolated according to Fàbrega et al. (30). The 301 
expression of acrB, acrF genes was analyzed by RT-qPCR (31). The 16S rRNA was 302 
used as an internal control gene for normalization. The relative expression level of 303 
each gene was calculated using the ΔΔCt method. Data is presented as mean ± SD. 304 
Three independent assays were performed, and each RNA sample was tested in 305 
triplicate. 306 
Fluorescence reporter plasmids for measuring expression of target genes 307 
 The promoter regions of acrA, ramA, marA, soxS were cloned into plasmid 308 
pMW82 to control gfp expression individually. Each resulting promoter fusion plasmid 309 
was transformed into strains by electroporation. Transformants were inoculated into 310 
LB broth containing 50 µg/mL carbenicillin (to maintain the plasmid) incubated at 311 
37 °C with shaking for around 12 hours and cultures were normalized at OD600 0.1. 312 
Three biological and three technical replicates were included in each assay. 200 µL 313 
of each normalized culture was added into wells of a 96-well plate and simultaneous 314 
measurement of fluorescence reader at excitation and emission of 485 nm and 520 315 
nm and absorbance at a wavelength of 600 nm were conducted at 37 °C in a BMG 316 
FLUOstar Omega plate reader every 10 minutes for 9 hours. 317 
Accumulation assays 318 
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Resazurin accumulation assays were used to assess differences in accumulation and 319 
efflux ability. Strains of interest were grown to log phase by 1:100 inoculation from 320 
overnight cultures. Cells were harvested, washed by PBS, and normalized at OD600 321 
0.1. 180 µL of normalized cultures were mixed with 10 µL of resazurin (to give a final 322 
concentration of 10 µg/mL) and 10 µL of pump inhibitor PAβN (to give a final 323 
concentration of 0.125 µg/mL) or only resazurin and transferred into a 96-well plate. 324 
Simultaneous measurement of fluorescence at excitation and emission of 544nm and 325 
590nm and absorbance at a wavelength of 600 nm were conducted in Omega 326 
FLUOstar plate reader every 5-10 minutes for few hours. Salmonella 14028s ∆ 327 
tolC::cat was used as a control strain. Three technical replicates and at least three 328 
biological replicates were conducted. Cell-only and resazurin-only reactions were set 329 
as controls. 330 
Bacterial growth kinetic and competition assays  331 
To determine growth kinetics, strains were incubated overnight in Luria-Bertani 332 
(LB) broth at 37°C with shaking, and diluted to OD600 = 0.1, then 30 μL was added 333 
into 15 mL fresh LB broth and incubated with shaking (200 rpm). Samples were 334 
serially diluted and plated onto LB agar plates to estimate growth every two hours. 335 
The plates were incubated at 37°C for 24 h before counting colonies. Three 336 
independent assays were performed for each strain.  337 
We tested competition between strains in 0%, 0.1%, and 1% bile in antibiotic-338 
free LB broth. Each test was run with nine replicates. The relative abundance of each 339 
strain in populations was determined using pyrosequencing to identify the single 340 
nucleotide variations in the strains according to the method of Baker et al (32). The 341 
DNA from the competitive growth assays was amplified by PCR in triplicate using 342 
biotinylated primer pairs targeting the region containing the single nucleotide 343 
polymorphism to distinguish the two organisms in the assay by mutations in the 344 
chromosome according to Single Nucleotide Polymorphisms (SNP) analyses based 345 
WGS (position: 1347348). All PCR amplifications were visualized on 1% agarose 346 
gels prior to pyrosequencing. The purified PCR products were pyrosequenced at the 347 
BGI Company. Competition coefficients were calculated by measuring the 348 
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percentage yield of the single nucleotide in the genome. A competition coefficient >1 349 
means that the resistant strain was the more abundant strain; meanwhile, a 350 
competition coefficient <1 means that the resistant strain was the less abundant 351 
strain. 352 
Competition assays between each subpopulation and Salmonella 14028s/lac (a 353 
S. Typhimurium14028s mutant carrying the lacIZ genes downstream of glmS) were 354 
also carried out to determine the competitive ability of the two subpopulations. 355 
Overnight cultures were normalized at an OD600 nm of 1. Each strain was (1:100) 356 
added into universals containing 5 mL LB broth. CFU of each strain were determined 357 
by plating appropriate dilutions on LB agar plates containing X-gal and IPTG (blue-358 
white screening) both at the beginning and after 24 hours of co-culturing at 37 °C. 359 
Competitive coefficients of each subpopulation against the 14028s/lac mutant strain 360 
were calculated between 0 hour and 24 hour time points. Two biological and three 361 
technical replicates were used. 362 
Adhesion, invasion assays and Galleria mellonella infection model 363 
The ability of strains to adhere to and invade INT 407 cells (human embryonic 364 
intestine cell line stored in our laboratory) was assayed using a previously described 365 
method (33). Each assay was performed at least three times with three technical 366 
replicates for each strain. 367 
Galleria mellonella larvae infection model was used to assay the virulence of 368 
different strains. Wax worm larvaes were purchased from livefoods.co.uk. Healthy 369 
larvae (no pupation or melanisation) of similar size were selected for bacteria 370 
injection. A preliminary which was conducted to determine the infectious dose of 371 
Salmonella (S. Typhimurium 14028s was used) found that an inoculation of 2*104 372 
CFU resulted in 50% lethality after 72 hours under 37 ℃. Overnight cultures of each 373 
strain were diluted and normalized in PBS and a certain volume of dilution were 374 
injected into the third hindmost left proleg of ten larvae. Inoculation were also 375 
confirmed by plating different dilutions onto LB agar plates and counting CFUs on the 376 
next day. PBS injection and no injections were included as controls. Survival rates 377 
were checked over time. 3 biological replicates were included in this experiment. 378 
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Genome sequencing 379 
For Illumina sequencing, DNA was prepared from 500 µL of overnight cultures 380 
using a standard alkaline lysis procedure. 50 µL of DNA- binding magnetic beads 381 
(KAPA Pure beads, Roche diagnostics) were used to purify DNA before beads were 382 
washed by fresh 80% ethanol three times and left to air dry for 1-2 minutes. 200 µL of 383 
5 mM Tris-Cl was added into each eppendorf and mixed by vortexing and pipetting 384 
for 5 minutes. The tubes were centrifuged for 10 minutes at 11,000 g and the isolated 385 
DNA was transferred into a new eppendorf. DNA was quantified using Qubit dsDNA 386 
HS Assay kit (Q32851) on a Qubit 3.0 instrument (Invitrogen, MA, USA) according to 387 
the manufacturer’s instructions. Genome sequencing was carried out on the Illumina 388 
NextSeq 500 platform (Illumina, San Diego, CA). Libraries were prepared using a 389 
Nextera XT DNA protocol from genomic DNA normalized to 0.5 ng/µL with 10 mM 390 
Tris-HCl. The final pool was quantified using Qubit dsDNA HS Assay kit (Q32851) on 391 
a Qubit 3.0 instrument (Invitrogen, MA, USA) and run on a high sensitivity D1000 392 
ScreenTape (Agilent Catalogue No. 5067-5579) using the Agilent Tapestation 4200 to 393 
calculate the final library pool molarity. The pool was run at a final concentration of 394 
1.8 pM on an Illumina NextSeq500 instrument using a mid-output. 395 
For Nanopore sequencing, strains were incubated overnight in LB broth at 37°C 396 
with shaking and the genomic DNA was extracted using the RevoluGen PuriSpin Fire 397 
Monkey Kit. DNA was quantified and qualified by Qubit dsDNA HS Assay kit on a 398 
Qubit 3.0 instrument (Invitrogen, MA, USA) and Genomic DNA screen Tape 399 
according to the manufacturer’s instructions. 400 
Libraries were prepared using the rapid barcoding kit (Oxford Nanopore 401 
catalogue number SQK-RBK004) according the manufacturer’s instructions. 400 ng 402 
DNA was used for library preparation and 75 µL of the library was loaded on an R9.4 403 
MinION flowcell. Size of the DNA fragments was assessed using the Agilent 2200 404 
Tape Station (Agilent Catalogue No. 5067-5579) before sequencing and after final 405 
library pool preparation.  406 
Hybrid assembly, annotations and SNP analyses 407 
Sequencing reads were uploaded to virtual machines provided by the MRC 408 
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CLIMB (the Cloud Infrastructure for Microbial Bioinformatics) project using 409 
BaseMount (34). Analyses of sequencing data used ‘NanoStat v 0.1.1’ to calculate 410 
statistics of long reads. Adapters from Oxford Nanopore reads were trimmed using 411 
‘Porechop v 0.2.3’. ‘NanoFilt v 0.1.0’ was used for filtering and trimming of long reads 412 
after Porechop bioinformatics analyses. ‘fastp v 0.19.5’ was used to provide all-in-one 413 
preprocessing for all FASTQ files. ‘MultiQC v 1.7’ was used to take results of fastp 414 
bioinformatics analyses and create a single report. Hybrid assemblies of Illumina and 415 
Nanopore reads after bioinformatics analyses were then performed using the 416 
Unicycler assembly pipeline for bacteria genomes and finally assemblies were then 417 
annotated with ‘Prokka v 1.13’. Annotations were visualized in ‘Artemis’. SNPs in 418 
isolates were identified using ‘Snippy v 4.2.3’. Comparison of the genomes of HZC9 419 
and HZC9-R was done by using BRIG (BLAST Ring Image Generator). 420 
Strains and genetic manipulation 421 
An rsxC gene deletion mutant was created using the λ-red recombineering 422 
system-based, gene doctoring technique as previously described(35). Two 423 
homologous regions which include 330 bp upstream and downstream of the part 424 
which would be deleted were amplified by PCR. Colony PCR and Sanger sequencing 425 
were carried out to check part deletion of rsxC with primers annealing outside the 426 
region to be modified.  427 
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Table 1. Susceptibility, genotypes and gene expression of strains used in the 549 





Target gene mutations 
PMQR 
Gene expression values (+ SEM) 
gyrA gyrB parC parE acrB acrF 
HZC9 0.25 ST13 Agona - - T57S - qnrS 1 1 
HZC9-R  4  ST13  Agona - - T57S - qnrS 2.43(1.23) 1.57(0.94) 
 551 
















HZC9 64 4 16 <0.125 0.5 4 128 
HZC9 ∆rsxC::tetR 128 4 64 <0.125 1 8 256 
HZC9-R 128 2 128 0.5 4 32 512 
ACR, Acriflavine; KAN, Kanamycin; AMP, Ampicillin; CEF, Cefotaxime; CIP, 553 
Ciprofloxacin; AZI, Azithromycin; CHL, Chloramphenicol; tetR, tetracycline resistance 554 
 555 
  556 
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     557 
Figure 1. Susceptibility of HZC9 to ciprofloxacin as demonstrated by population 558 
analyses and PFGE profiles of Xbal-digested genomic DNA of HZC9 and HZC9-R. 559 




Figure 2. (a) Relative expression of qnrS in HZC9 and HZC9-R. Values show mean ± 564 
SD from three independent assays with three technical replicates in each. (b) 565 
Resazurin accumulation by HZC9, HZC9-R (and reference strain tolC::cat). Values 566 
shown mean data from three experiments, each with three technical replicates. 567 
 568 





Figure 3. (a) In vitro bacterial competition assays by blue-white screening. 572 
Competition coefficient values obtained from each independent experiment are 573 
plotted; a competition coefficient of 1 is noted by a horizontal line. (b) In vitro bacterial 574 
competition assays by pyrosequencing. Competition coefficient values obtained from 575 
each independent experiment are plotted; means are noted by short continuous 576 





Figure 4. (a) Ability of strains to associate and invade INT 407 epithelial cells. 582 
Results are the mean of three independent experiments ±standard error. (b) 583 
Virulence of strains in a Galleria mellonella larvae infection model. Survival numbers 584 
were counted over time. 585 
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Figure 5. Expression of soxS in HZC9 and HZC9-R measured by gfp-reporter 587 
assays. Fluorescence was measured in arbitrary units and data show averages from 588 
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Supplemental Material 599 
Figure legends 600 
Figure S1. Map of genomic comparison of HZC9 (CZ1) and HZC9-R (CZ5). HZC9 601 
(CZ1) was used as the reference. Four contigs on the map represent chromosome, 602 
plasmid 1, plasmid 2 and plasmid 3 individually.                                                                                                                                                                                                                             603 
 604 
 605 
  606 
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Table S1. Genetic differences between HZC9 and HZC9-R. 607 
 608 
 HZC9 (CZ1) HZC9-R (CZ5) Difference 
Chromosome (bp) 4,972,924 4,972,563 -361 
Plasmid 1 (bp) 92,109 92,110 +1 
Plasmid 2 (bp) 49,297 48,872 -425 
Plasmid 3 (bp) 10,047 10,047 = 
 609 
Table S2. Single-Nucleotide Polymorphisms (SNPs) found between two strains 610 
Gene 
Position and SNPs 
1183585 1347348 1902973 2330556 2337500 2633210 
motB hypothetical sifA hypothetical intergenic hypothetical 
HZC9 C C G A C G 
HZC9-R A T A T T A 
 611 
